Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Thumbnail

What the EVALI epidemic means for public health

The jury is out: vaping, or e-cigarette use, is a national epidemic in the U.S.

Thumbnail

Nonprofit shells out $5.7M for research on single ventricle heart defects

Palo Alto, Calif.-based nonprofit Additional Ventures announced Jan. 21 it would be awarding a total of $5.7 million to five institutions for research on single ventricle heart defects.

Death, amputation more common with paclitaxel-coated devices vs. conventional angioplasty

A recent meta-analysis published in the Journal of Vascular and Interventional Radiology supports evidence that paclitaxel-coated balloons may pose more risk than reward for patients with symptoms of critical limb ischemia.

Thumbnail

FDA approves world’s smallest pacemaker with AV synchrony

Medtronic announced Jan. 21 it had received FDA approval for its Micra AV device—the world’s smallest pacemaker with atrioventricular synchrony.

Thumbnail

How 7 North Carolina clinics increased patient use of statins by 349%

A two-year collaboration between the North Carolina chapter of the American College of Cardiology and North Carolina Association of Free and Charitable Clinics was successful in providing thousands of underserved heart patients with free lipid-lowering therapy and clopidogrel.

Thumbnail

The most physically inactive states, ranked

More than 15% of adults in all U.S. states and territories were physically inactive between 2015 and 2018, according to recent data from the CDC, with estimates ranging from 17.3% to 47.7% between regions.

Thumbnail

Experimental hemophilia drug could be the most expensive in the world

Biotech company BioMarin Pharmaceutical is considering a price point of between $2 million and $3 million for its novel experimental gene therapy for hemophilia patients, the Wall Street Journal reported Jan. 16.

Thumbnail

More than 2M heart patients use marijuana

A review published in the Journal of the American College of Cardiology this month suggests that an excess of 2 million patients with cardiovascular disease also use marijuana.